🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +21.72% on $IMNM in just 19h 36m.
CAR
$CARM
🔒 US EquitiesCarisma Therapeutics, Inc.
AVG HISTORICAL GAP
+0.94%
MAX GAP RECORD
+5.00%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $CARM
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$CARM
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE) |
+0.73%
|
| Mar 31, 2025 Earnings Release 2025-03-31 (AFTER CLOSE) |
-3.23%
|
| Nov 07, 2024 Earnings Release 2024-11-07 (BEFORE OPEN) |
-2.70%
|
| Aug 08, 2024 Earnings Release 2024-08-08 (BEFORE OPEN) |
+5.00%
|
| Apr 02, 2024 Earnings Release 2024-04-02 (BEFORE OPEN) |
+2.39%
|
| Nov 09, 2023 Earnings Release 2023-11-09 (BEFORE OPEN) |
+3.69%
|
| Aug 10, 2023 Earnings Release 2023-08-10 (BEFORE OPEN) |
+0.72%
|
| May 11, 2023 Earnings Release 2023-05-11 (BEFORE OPEN) |
+0.00%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
2.6%
Bullish Gaps (3)
Bearish Gaps (2)
Neutral / Flat (2)
📖 Intelligence Summary
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗